KRAS mutational status impacts pathologic response to pre-hepatectomy chemotherapy: a study from the International Genetic Consortium for Liver Metastases

KRAS mutational status impacts pathologic response to pre-hepatectomy chemotherapy: a study from the International Genetic Consortium for Liver Metastases

A major response to pre-hepatectomy chemotherapy has been associated with improved survival in patients who undergo resection of colorectal liver metastases (CRLM). However, the role of tumor biology, as exemplified by overall and codon-specific KRAS mutational status, in predicting response to chem...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:HPB (Oxford, England) England), 2019-11, Vol.21 (11), p.1527-1534
Hauptverfasser: Margonis, Georgios A., Amini, Neda, Andreatos, Nikolaos, Sasaki, Kazunari, McVey, Jack, Mirza, Muhammad B., Warner, Samuel, Buettner, Stefan, Barbon, Carlotta, Wang, Jane, Pulvirenti, Alessandra, Angelou, Anastasios, Kamphues, Carsten, Antoniou, Efstathios, Pikoulis, Emmanouil, Pawlik, Timothy M., Kaczirek, Klaus, Poultsides, George, Wagner, Doris, Endo, Itaru, Imai, Katsunori, Aucejo, Federico, Kreis, Martin E., Wolfgang, Christopher L., Weiss, Matthew J.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A major response to pre-hepatectomy chemotherapy has been associated with improved survival in patients who undergo resection of colorectal liver metastases (CRLM). However, the role of tumor biology, as exemplified by overall and codon-specific KRAS mutational status, in predicting response to chemotherapy is not well defined. Pathologic response was characterized as minor or major depending on the percentage of remnant viable cells (>50% vs
ISSN:1365-182X
1477-2574
DOI:10.1016/j.hpb.2019.03.368